

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 August 2020 (27.08.2020)



(10) International Publication Number
WO 2020/172421 A1

(51) International Patent Classification:

C07H 21/02 (2006.01) C07K 16/40 (2006.01)
C07H 21/04 (2006.01) C12N 15/63 (2006.01)
C07K 16/00 (2006.01) C12P 21/08 (2006.01)

(21) International Application Number:

PCT/US2020/019059

(22) International Filing Date:

20 February 2020 (20.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/808,137 20 February 2019 (20.02.2019) US

(71) Applicant: **RENEO PHARMACEUTICALS, INC.**

[US/US]; 12230 El Camino Real, Suite 230, San Diego, California 92130 (US).

(72) Inventors: **O'CARROLL, Colin**; 12230 El Camino

Real, Suite 230, San Diego, California 92130 (US).

O'DONNELL, Niall; 12230 El Camino Real, Suite 230, San Diego, California 92130 (US). **PURKINS, Lynn**; 12230 El Camino Real, Suite 230, San Diego, California 92130 (US). **DORENBAUM, Alex**; 12230 El Camino Real, Suite 230, San Diego, California 92130 (US).

(74) Agent: **ZUNIC, Valentin B.**; WILSON SONSINI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY




FIG. 1

(57) Abstract: Described herein is the use of PPAR6 agonists in the treatment of mitochondrial myopathy. In one aspect, described herein are methods for treating a primary mitochondrial myopathy (PMM) in a mammal comprising administering to the mammal with a primary mitochondrial myopathy a peroxisome proliferator-activated receptor delta (PPAR6) agonist compound. In another aspect, described herein is a method of modulating PPAR6 in a mammal with primary mitochondrial myopathy comprising administering to the mammal with primary mitochondrial myopathy PPAR6 agonist compound.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*